Back
Lam Research 10K Form
Sell
42
LRCX
Lam Research
Last Price:
733.53
Seasonality Move:
5.41%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-04-29 | 10Q | LRCX/Lam Research Quarterly |
2024-01-29 | 10Q | LRCX/Lam Research Quarterly |
2023-10-23 | 10Q | LRCX/Lam Research Quarterly |
2023-08-15 | 10K | LRCX/Lam Research Annual |
2023-04-24 | 10Q | LRCX/Lam Research Quarterly |
2023-01-30 | 10Q | LRCX/Lam Research Quarterly |
Receive LRCX News And Ratings
See the #1 stock for the next 7 days that we like better than LRCX
LRCX Financial Statistics
Sales & Book Value
Annual Sales: | $14.91B |
---|---|
Cash Flow: | $761.68M |
Price / Cash Flow: | 22.75 |
Annual Sales: | $65.50 |
Price / Book: | 11.16 |
Profitability
EPS (TTM): | 29.00000 |
---|---|
Net Income (TTM): | $3.83B |
Gross Margin: | $7.05B |
Return on Equity: | 46.63% |
Return on Assets: | 20.55% |
Lam Research Earnings Forecast
Key Lam Research Financial Ratios
- The Gross Profit Margin over the past 41 years for LRCX is 47.32%.
- The Selling, General & Administrative Expenses for LRCX have been equal to 5.83% of Gross Profit Margin.
- The Research & Development expenses have been 12.76% of Revenue.
- The Interest Expense is 4.84% of Operating Income.
- The Net Earning history of LRCX is 25.68% of Total Revenues.
- Per Share Earnings over the last 41 years have been positive in 28 years.
Lam Research Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Semiconductors & Semiconductor Equipment |
Sector: | Information Technology |
Current Symbol: | LRCX |
CUSIP: | 512807 |
Website: | lamresearch.com |
Debt
Debt-to-Equity Ratio: | 0.58 |
---|---|
Current Ratio: | 2.97 |
Quick Ratio: | 1.93 |
Price-to-Earnings
Trailing P/E Ratio: | 25.29 |
---|---|
Forward P/E Ratio: | 15.94 |
LRCX Technical Analysis vs Fundamental Analysis
Sell
42
Lam Research (LRCX)
is a Sell
Is Lam Research a Buy or a Sell?
-
Lam Research stock is rated a Sell
The current Lam Research [LRCX] share price is $733.53. The Score for LRCX is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.